硝苯地平在雷诺现象中的临床及血液流变学效应
Clinical and rheological effects of nifedipine in Raynaud's phenomenon.
作者信息
Waller D G, Challenor V F, Francis D A, Roath O S
出版信息
Br J Clin Pharmacol. 1986 Oct;22(4):449-54. doi: 10.1111/j.1365-2125.1986.tb02916.x.
Abstract
Thirty-four patients with Raynaud's phenomenon, 28 primary and six secondary, were entered into a double-blind placebo controlled, randomized cross-over trial of nifedipine treatment. Nifedipine was given as a 20 mg biphasic release formulation twice daily. Twenty-nine patients completed the study, during which the mean number of attacks was reduced by 25% during nifedipine treatment (P less than 0.001). Twenty patients scored nifedipine higher than placebo on a five point rating scale (P less than 0.001). Unwanted effects were experienced by 26 patients during active treatment, resulting in withdrawal from the study in five. Red cell deformability and fibrinogen concentrations were not altered by nifedipine.
摘要
34例雷诺现象患者（28例原发性，6例继发性）进入硝苯地平治疗的双盲安慰剂对照随机交叉试验。硝苯地平采用20mg双相释放制剂，每日2次给药。29例患者完成了研究，在此期间，硝苯地平治疗期间发作的平均次数减少了25%（P<0.001）。在五点评分量表上，20例患者对硝苯地平的评分高于安慰剂（P<0.001）。26例患者在积极治疗期间出现了不良反应，导致5例退出研究。硝苯地平未改变红细胞变形性和纤维蛋白原浓度。
相似文献
1
Clinical and rheological effects of nifedipine in Raynaud's phenomenon.硝苯地平在雷诺现象中的临床及血液流变学效应
Br J Clin Pharmacol. 1986 Oct;22(4):449-54. doi: 10.1111/j.1365-2125.1986.tb02916.x.
2
A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon.
Eur Heart J. 1986 Feb;7(2):165-70. doi: 10.1093/oxfordjournals.eurheartj.a062040.
3
Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.硝苯地平治疗雷诺现象的对照试验。
Lancet. 1982 Dec 11;2(8311):1299-301. doi: 10.1016/s0140-6736(82)91508-2.
4
Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon.硝苯地平治疗特发性雷诺现象临床疗效的对照双盲试验
Am Heart J. 1986 Apr;111(4):742-5. doi: 10.1016/0002-8703(86)90109-2.
5
Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon.
Angiology. 1989 Feb;40(2):122-8. doi: 10.1177/000331978904000207.
6
Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.静脉输注伊洛前列素与口服硝苯地平治疗系统性硬化症患者雷诺现象的比较：一项双盲随机研究。
BMJ. 1989 Mar 4;298(6673):561-4. doi: 10.1136/bmj.298.6673.561.
7
Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.硝苯地平治疗系统性硬化症患者的雷诺现象。
Br J Dermatol. 1987 Aug;117(2):237-41. doi: 10.1111/j.1365-2133.1987.tb04122.x.
8
Nisoldipine in primary Raynaud's phenomenon.尼索地平治疗原发性雷诺现象。
Eur J Clin Pharmacol. 1987;33(1):27-30. doi: 10.1007/BF00610375.
9
Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon.达唑氧苯与硝苯地平治疗雷诺现象的对照双盲试验。
Am J Med. 1984 Sep;77(3):451-6. doi: 10.1016/0002-9343(84)90101-3.
10
Nifedipine in the treatment of idiopathic Raynaud's syndrome.硝苯地平治疗特发性雷诺综合征
J Rheumatol. 1986 Apr;13(2):331-6.
引用本文的文献
1
Calcium channel blockers for primary and secondary Raynaud's phenomenon.用于原发性和继发性雷诺现象的钙通道阻滞剂。
Cochrane Database Syst Rev. 2017 Dec 13;12(12):CD000467. doi: 10.1002/14651858.CD000467.pub2.
2
Calcium channel blockers for primary Raynaud's phenomenon.用于原发性雷诺现象的钙通道阻滞剂。
Cochrane Database Syst Rev. 2016 Feb 25;2(2):CD002069. doi: 10.1002/14651858.CD002069.pub5.
3
Raynaud's phenomenon (primary).雷诺现象（原发性）
BMJ Clin Evid. 2013 Oct 10;2013:1119.
4
Raynaud's phenomenon (primary).雷诺现象（原发性）
BMJ Clin Evid. 2011 Mar 14;2011:1119.
5
Raynaud's phenomenon (primary).雷诺现象（原发性）
BMJ Clin Evid. 2008 Dec 16;2008:1119.
6
Pharmacotherapy of Raynaud's phenomenon.雷诺现象的药物治疗。
Drugs. 1996 Nov;52(5):682-95. doi: 10.2165/00003495-199652050-00006.
7
Nisoldipine in primary Raynaud's phenomenon.尼索地平治疗原发性雷诺现象。
Eur J Clin Pharmacol. 1987;33(1):27-30. doi: 10.1007/BF00610375.
8
The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.尼索地平对雷诺现象患者全血血小板聚集的影响。
Br J Clin Pharmacol. 1988 Jun;25(6):751-4. doi: 10.1111/j.1365-2125.1988.tb05262.x.
9
Management of Raynaud's phenomenon. Focus on newer treatments.雷诺现象的管理。聚焦于新型治疗方法。
Drugs. 1989 May;37(5):700-12. doi: 10.2165/00003495-198937050-00005.
10
Nifedipine and alpha-adrenoceptor function in human finger skin vessels.硝苯地平与人体手指皮肤血管中的α-肾上腺素能受体功能
Eur J Clin Pharmacol. 1989;37(2):107-10. doi: 10.1007/BF00558215.
本文引用的文献
1
Nifedipine plasma concentration in patients treated for angina pectoris.接受心绞痛治疗患者的硝苯地平血浆浓度。
Int J Clin Pharmacol Ther Toxicol. 1984 Apr;22(4):198-203.
2
The acute effects of nifedipine on red cell deformability in angina pectoris.硝苯地平对心绞痛患者红细胞变形能力的急性影响。
Br J Clin Pharmacol. 1984 Feb;17(2):133-8. doi: 10.1111/j.1365-2125.1984.tb02327.x.
3
Treatment of digital vasospastic disease with the calcium-entry blocker nifedipine.用钙通道阻滞剂硝苯地平治疗指端血管痉挛性疾病。
Acta Med Scand. 1984;215(2):135-9. doi: 10.1111/j.0954-6820.1984.tb04983.x.
4
Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon.达唑氧苯与硝苯地平治疗雷诺现象的对照双盲试验。
Am J Med. 1984 Sep;77(3):451-6. doi: 10.1016/0002-9343(84)90101-3.
5
Haemorrheological effects of prostaglandin E1 infusion in Raynaud's syndrome.前列腺素E1输注对雷诺综合征的血液流变学影响。
J Clin Pathol. 1984 Aug;37(8):870-3. doi: 10.1136/jcp.37.8.870.
6
The first pass metabolism of nifedipine in man.硝苯地平在人体中的首过代谢。
Br J Clin Pharmacol. 1984 Dec;18(6):951-4. doi: 10.1111/j.1365-2125.1984.tb02569.x.
7
Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon.
Am Heart J. 1984 Aug;108(2):370-3. doi: 10.1016/0002-8703(84)90627-6.
8
Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.钙通道阻滞剂硝苯地平对雷诺现象的影响。一项对照双盲试验。
J Rheumatol. 1984 Jun;11(3):362-4.
9
Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon).钙通道阻滞剂治疗指端血管痉挛（雷诺现象）
Eur Heart J. 1983 May;4 Suppl C:123-9. doi: 10.1093/eurheartj/4.suppl_c.123.
10
Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.硝苯地平治疗雷诺现象的对照双盲试验。
N Engl J Med. 1983 Apr 14;308(15):880-3. doi: 10.1056/NEJM198304143081507.
Zotero 插件